Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy

Area of Science:

• Endocrinology
• Bone Biology
• Gynecology

Background:

• Hormone replacement therapy (HRT) is used to prevent postmenopausal bone loss and fractures.
• Conventional HRT carries risks like increased breast and uterine cancer. Long-cycle HRT offers a potential alternative with extended progesterone-free intervals.
• The impact of long-cycle HRT on bone health is not well understood.

Purpose of the Study:

• To compare the effects of long-cycle HRT and conventional HRT on bone mineral density (BMD) and endometrial health.
• To evaluate the efficacy of long-cycle HRT in preventing postmenopausal bone loss.

Main Methods:

• A randomized study involving 73 healthy non-hysterectomized postmenopausal women.
• Participants were assigned to either conventional HRT or long-cycle HRT regimens for 24 months.
• The primary endpoint was the change in lumbar spine bone mineral density (BMD).

Main Results:

• Both conventional HRT and long-cycle HRT significantly increased lumbar spine BMD compared to baseline (3.8% and 3.3%, respectively).
• No significant difference in BMD changes was observed between the two treatment groups.
• BMD also increased at the femoral neck, and biochemical markers of bone turnover decreased significantly in both groups. No adverse endometrial or breast events were reported.

Conclusions:

• Long-cycle HRT demonstrates comparable efficacy to conventional HRT in protecting against postmenopausal bone loss.
• Long-cycle HRT may serve as a viable alternative for managing bone health in postmenopausal women.